From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:17:36 +0000 Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730 Fax 212-376-3190 Cell 917-922-7391 dictated and sent from an iPhone kindly excuse typos Begin forwarded message: From: Cardiology Alert < Date: March 24, 2017 at 7:06:06 AM EDT To: <I a Subject: FOURIER: Significant LDL Reduction with Evolocumab Reply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2017 American College of Cardiology Scientific Session in Washington, M. suggested that evolocumab was associated with significant reductions in LDL cholesterol in patients with atherosclerotic cardiovascular disease and elevated LDL. The PCSK9 inhibitor evolocumab was the subject of the study. The research team sought to determine the safety and clinical efficacy of the drug when added to statin therapy in patients who have clinically evident atherosclerotic EFTA00447981